Aktien Sensor

Ono Pharmaceutical Co Ltd is set to announce its quarterly earnings on August 1st, with analysts predicting an 8.82% rise in sales.

Merck & Co Inc. has unveiled a comprehensive restructuring plan to address declining sales and profits, aiming to save $3 billion annually and redirect funds towards growth areas and new medicine development.

Sanofi has reported a strong second quarter, driven by sales growth from its blockbuster medication Dupixent, and has raised its sales guidance for the year.

Regeneron Pharmaceuticals is set to report its Q2 earnings on August 1st, with analysts forecasting a decline in earnings per share amidst industry growth driven by biosimilars and affordable biologics.

Eisai’s LEQEMBI treatment has been shown to slow down the progression of Alzheimer’s disease in patients with early Alzheimer’s disease, marking a major breakthrough in the fight against the disease.

Neurocrine Biosciences Inc. has exceeded expectations with a 17% year-over-year growth in total net product sales, driven by strong performance of its key products INGREZZA and CRENESSITY.

Bristol-Myers Squibb has reported a strong second-quarter earnings performance, exceeding expectations with a 4.1% revenue increase and 36.4% rise in adjusted earnings per share.

Takeda Pharmaceutical’s quarterly results showed a decline in revenue and earnings, but a more nuanced picture emerged with a decrease in core operating profit and an increase in reported operating profit, despite a 2.5% drop in stock price.

Illumina Inc. has unveiled a new cancer research assay, TruSight Oncology 500 v2, which is expected to accelerate precision medicine and improve patient outcomes through comprehensive genomic profiling and molecular tumor analysis.

Revvity Inc’s stock price has declined to $90 per share after the company reported mixed second-quarter earnings and trimmed its adjusted financial guidance.